

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names: List 63

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/ERC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES: Liste 63

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/ERC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS: Lista 63

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/ERC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

**acidum obeticholicum**

obeticholic acid

6 $\alpha$ -ethyl-3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oic acid


acide obéticholique

acide 6 $\alpha$ -éthyl-3 $\alpha$ ,7 $\alpha$ -dihydroxy-5 $\beta$ -cholan-24-oïque

ácido obeticólico

ácido 6 $\alpha$ -etil-3 $\alpha$ ,7 $\alpha$ -dihidroxi-5 $\beta$ -colan-24-oico

C<sub>26</sub>H<sub>44</sub>O<sub>4</sub>



**acidum tiomolibdicum**

tiomolibdic acid

dihydrogen(tetrasulfidomolybdate)


acide tiomolibdique

tétrasulfidomolybdate d'hydrogène

ácido tiomolibdico

dihidrógeno(tetrasulfuomolibdato)

H<sub>2</sub>MoS<sub>4</sub>



**afacifenacinum**

afacifenacin



(4S)-4-phenyl-3-(1-([3-(trifluoromethoxy)phenyl]methyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one

afacifénacine

(4S)-4-phényl-3-(1-([3-(trifluorométhoxy)phényl]méthyl)pipéridin-4-yl)-3,4-dihydroquinazolin-2(1H)-one

afacifenacina

(4S)-4-fenil-3-(1-([3-(trifluorometoxi)fenil]metil)piperidin-4-il)-3,4-dihidroquinazolin-2(1H)-ona

**afegostat**



afegostat

(3*R*,4*R*,5*R*)-5-(hydroxymethyl)piperidine-3,4-diol

afégostat

(3*R*,4*R*,5*R*)-5-(hydroxyméthyl)pipéridine-3,4-diol

afegostat



(3*R*,4*R*,5*R*)-5-(hidroximetil)piperidina-3,4-diol**aganirsenum**

aganirsenum

*all-P-ambo*-thymidylyl-(3' → 5')-2'-deoxy-*P*-thioadenylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thioadenylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-2'-deoxy-*P*-thioadenylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-deoxy-*P*-thioguanylyl-(3' → 5')-2'-deoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidine

aganirsenum

*tout-P-ambo-P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thioadénylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-2'-déoxy-*P*-thioadénylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-*P*-thiothymidylyl-(3' → 5')-2'-déoxy-*P*-thioguanylyl-(3' → 5')-2'-déoxy-*P*-thiocytidylyl-(3' → 5')-thymidine

|                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| aganirsén                                      | <p><i>todo-P-ambo</i>-timidilil-(3'→5')-2'-desoxi-<i>P</i>-tioadenilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-desoxi-<i>P</i>-tioadenilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-2'-desoxi-<i>P</i>-tioadenilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-<i>P</i>-tiotimidilil-(3'→5')-2'-desoxi-<i>P</i>-tioguanilil-(3'→5')-2'-desoxi-<i>P</i>-tiocitidilil-(3'→5')-<i>P</i>-tiotimidina</p> <p><math>C_{242}H_{307}N_{91}O_{127}P_{24}S_{24}</math></p> <p>(3'-5')d(<i>P</i>-thio)(T-A-T-C-C-G-G-A-G-G-G-C-T-C-G-C-C-A-T-G-C-T-G-C-T)</p> |
| albitiazolii bromidum<br>albitiazolium bromide | <p>3,3'-(dodecan-1,12-diyl)bis[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium] dibromide</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| bromure d'albitiazolium                        | dibromure de 3,3'-(dodécane-1,12-diyl)bis[5-(2-hydroxyéthyl)-4-méthyl-1,3-thiazol-3-ium]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| bromuro de albitiazolio                        | dibromuro de 3,3'-(dodecan-1,12-diil)bis[5-(2-hidroxietil)-4-metil-1,3-tiazol-3-io]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                | <p><math>C_{24}H_{42}Br_2N_2O_2S_2</math></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| arhalofenatum<br>arhalofenate                  | <p>2-(acetamido)ethyl (2<i>R</i>)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| arhalofénate                                   | (2 <i>R</i> )-2-(4-chlorophényl)-2-[3-(trifluorométhyl)phénoxy]acétate de 2-(acétylamino)éthyle                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| arhalofenato                                   | (2 <i>R</i> )-2-(4-clorofenil)-2-[3-(trifluorometil)fenoxi]acetato de 2-(acetamido)etilo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                | <p><math>C_{19}H_{17}ClF_3NO_4</math></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

**ataluren**

ataluren


3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

ataluren

acide 3-[5-(2-fluorophényl)-1,2,4-oxadiazol-3-yl]benzoïque

atalureno

ácido 3-[5-(2-fluorofenil)-1,2,4-oxadiazol-3-il]benzoico

 $C_{15}H_9FN_2O_3$ **atiratecanum**


atiratecan

(9*S*)-9-ethyl-10,13-dioxo-1-pentyl-9,10,13,15-tetrahydro-1*H*,12*H*-pyrano[3'',4'':6',7']indolizino[2',1':5,6]pyrido[4,3,2-*de*]quinazolin-9-yl glycy-*N*-methylglycinate

atiratécán

glycyl-*N*-méthylglycinate de (9*S*)-9-éthyl-10,13-dioxo-1-pentyl-9,10,13,15-tétrahydro-1*H*,12*H*-pyrano[3'',4'':6',7']indolizino[2',1':5,6]pyrido[4,3,2-*de*]quinazolin-9-yle

atiratecán

glicil-*N*-metilglicinato de (9*S*)-9-etil-10,13-dioxo-1-pentil-9,10,13,15-tetrahidro-1*H*,12*H*-pirano[3'',4'':6',7']indolizino[2',1':5,6]pirido[4,3,2-*de*]quinazolin-9-ilo $C_{31}H_{34}N_6O_6$ **bardoxolonum**

bardoxolone


2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid

bardoxolone

acide 2-cyano-3,12-dioxooléana-1,9(11)-dién-28-oïque

bardoxolona

ácido 2-ciano-3,12-dioxooleana-1,9(11)-dien-28-oico

 $C_{31}H_{34}N_6O_6$ 

**beclanorsenum**  
beclanorsen

*all-P-ambo-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-2'-O,4'-C-methylene-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(3'→5')-2'-deoxyadenosine*

## béclanorsen


*tout-P-ambo-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiouridylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-5-méthyl-2'-O,4'-C-méthylène-P-thiocytidylyl-(3'→5')-2'-déoxyadénosine*

## beclanorsén

*todo-P-ambo-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-O,4'-C-metileno-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-5-metil-2'-O,4'-C-metileno-P-tiocitidilil-(3'→5')-2'-desoxiadenosina*

C<sub>159</sub>H<sub>201</sub>N<sub>58</sub>O<sub>82</sub>P<sub>15</sub>S<sub>15</sub>

(3'-5')d(P-thio)(mrC-rT-C-C-C-A-A-C-G-T-G-C-G-mrC-mrC-A)

**bixalomerum**  
bixalomer



cross linked polymer made of *N,N,N',N'*-tetrakis(3-aminopropyl)butane-1,4-diamine *N* substituted by bivalent substituent groups 2-hydroxypropane-1,2-diyl and 1-(hydroxymethyl)ethylene ( $x=20$ ,  $45 \leq y \leq 50$ )

## bixalomère

*N,N,N',N'*-tétrakis(3-aminopropyl)butane-1,4-diamine *N* substituée par les groupes substituants divalents 2-hydroxypropane-1,2-diyle et 1-(hydroxyméthyl)éthylène pour former un polymère réticulé ( $x=20$ ,  $45 \leq y \leq 50$ )

## bixalómero

*N,N,N',N'*-tétrakis(3-aminopropil)butano-1,4-diamina *N* substituida por los grupos sustituyentes divalentes 2-hidroxipropano-1,2-diilo y 1-(hidroximetil)etileno para formar un polímero reticulado ( $x=20$ ,  $45 \leq y \leq 50$ )



**briakinumabum #**  
briakinumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* interleukin 12 beta subunit (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40)], *Homo sapiens* monoclonal antibody;  
gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV3-30\*02 (99.00%) -(IGHD)-IGHJ3\*01) [8.8.8] (1-115) -IGHG1\*03 R120>K (116-445)], (218-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44\*01 (88.20%) -IGLJ2\*01 G120>T) [8.3.12] (1'-111') -IGLC2\*01 (112'-217')]; (224-224":227-227")-bisdisulfide dimer

briakinumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* interleukine 12 sous-unité bêta (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40)], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV3-30\*02 (99.00%) -(IGHD)-IGHJ3\*01) [8.8.8] (1-115) -IGHG1\*03 R120>K (116-445)], (218-216')-disulfure avec la chaîne légère kappa (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44\*01 (88.20%) -IGLJ2\*01 G120>T) [8.3.12] (1'-111') -IGLC2\*01 (112'-217')]; dimère (224-224":227-227")-bisdisulfure

briakinumab

inmunoglobulina G1-lambda, anti-[interleukina 12 subunidad beta (IL12B, IL-12B, IL12 p40, NKSF2, CMLF p40) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV3-30\*02 (99.00%) -(IGHD)-IGHJ3\*01) [8.8.8] (1-115) -IGHG1\*03 R120>K (116-445)], (218-216')-disulfuro con la cadena ligera kappa (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-44\*01 (88.20%) -IGLJ2\*01 G120>T) [8.3.12] (1'-111') -IGLC2\*01 (112'-217')]; dímero (224-224":227-227")-bisdisulfuro

$C_{6376}H_{9874}N_{1722}O_{1992}S_{44}$

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPGRLRL SCAASGFTFS SYGMHWVRQA PGKLEWVAF 50  
 IRYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCKTHG 100  
 SHDNWGQGTMT VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150  
 PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTPPSSS LGTQTYICNV 200  
 NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250  
 ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300  
 VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTL 350  
 PSREEMTKNQ VSLTCLVKG FSPDI AVEWE SNGQPENNYK TTPPVLDSDG 400  
 SFFLYSKLTV DKSRWQQGNV FSCSVMEAL HNHYTQKSL S LSPGK 445

Light chain / Chaîne légère / Cadena ligera

QSVLTQPPSV SGAPGQRVTI SCSSRSNIG SNTVKWYQQL PGTAPKLLIY 50  
 YNDQRPSPVP DRFSGSKSGT SASLAITGLQ AEDEADYYCQ SYDRYTHPAL 100  
 LFGTGKTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150  
 VAWKADSSPV KAGVETTPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200  
 THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 142-198 259-319 365-423  
 22"-96" 142"-198" 259"-319" 365"-423"  
 Intra-L 22'-89' 139'-198'  
 22'"-89'" 139'"-198'"  
 Inter-H-L 218-216' 218"-216"  
 Inter-H-H 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

295, 295"

**budiodaronum**

budiodarone

(2S)-butan-2-yl 2-(3-{4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl}-1-benzofuran-2-yl)acetate


budiodarone

2-(3-{4-[2-(diéthylamino)éthoxy]-3,5-diiodobenzoyl}-1-benzofuran-2-yl)acétate de (2S)-butan-2-yl

budiodarona

2-(3-{4-[2-(dietilamino)etoxi]-3,5-diiodobenzoil}-1-benzofuran-2-il)acetato de (2S)-butan-2-ilo

$C_{27}H_{31}I_2NO_5$



**burapitantum**

burapitant



2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl}piperidin-4-yl)-2-methylpropanamide

burapitant

2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluorométhyl)phényl]acétyl}-2-(3,4-dichlorophényl)morpholin-2-yl]éthyl}pipéridin-4-yl)-2-méthylpropanamide

burapitant

2-(1-{2-[(2R)-4-{2-[3,5-bis(trifluorometil)fenil]acetil}-2-(3,4-diclorofenil)morfolin-2-il]etil}piperidin-4-il)-2-metilpropanamida

**danegaptidum**

danegaptide



(2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid

danégaptide

acide (2S,4R)-1-(2-aminoacétyl)-4-benzamidopyrrolidine-2-carboxylique

danegaptida

ácido (2S,4R)-1-(2-aminoacetil)-4-benzamidopirrolidina-2-carboxílico

**daratumumabum #**

daratumumab


immunoglobulin G1-kappa, anti-[*Homo sapiens* ADP-ribosyl cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], *Homo sapiens* monoclonal antibody;  
 gamma1 heavy chain (1-452) [*Homo sapiens* VH (IGHV3-23\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; (231-231'':234-234'')-bisdisulfide dimer

daratumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ADP-ribosyl cyclase 1 (CD38, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, T10)], *Homo sapiens* anticorps monoclonal;  
 chaîne lourde gamma1 (1-452) [*Homo sapiens* VH (IGHV3-23\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure

daratumumab

inmunoglobulina G1-kappa, anti-[ADP-ribosil ciclaza 1 de *Homo sapiens* (CD38, hidrolasa 1 de ADP ciclico-ribosa, cADPr hidrolasa 1, T10)], anticuerpo monoclonal de *Homo sapiens*;  
 cadena pesada gamma1 (1-452) [*Homo sapiens* VH (IGHV3-23\*01 (94.90%) -(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -IGHG1\*03 (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ1\*01) [6.3.9] (1'-107') -IGKC\*01 (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro



## Heavy chain / Chaîne lourde / Cadena pesada

EVQLLES GGG LVQPGGSLRL SCAVSGFTFN SFAMSWVRQA PGKGLEWVSA 50  
 ISGSGGGTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYFCAKDK 100  
 ILWFGEPVFD YWQGGLTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150  
 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPVSSSLGT 200  
 QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250  
 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300  
 YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350  
 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTT 400  
 PVLDSGDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP 450  
 GK 452

## Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50  
 ASNRATGIPA RFSGSGSGTD FTLTISLSEP EDFAVYYCQ RSNWPPFTFGQ 100  
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150  
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200  
 LSSPVTKSFN RGEK 214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-205 266-326 372-430  
 22"-96" 149"-205" 266"-326" 372"-430"  
 Intra-L 23'-88' 134'-194'  
 23'''-88''' 134'''-194'''  
 Inter-H-L 225-214' 225"-214"  
 Inter-H-H 231-231" 234-234"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

302, 302"

davalintidum #  
davalintide

## amylin analogue

human islet amyloid polypeptide-(1-7)-peptidyl-  
 [11-L-arginine(K>R), 18-L-arginine(K>R)]salmon  
 calcitonin-1 (*Oncorhynchus keta*)-(8-27)-peptidyl-human islet  
 amyloid polypeptide-(33-37)-peptidamide

## davalintide

## analogue de l'amyline

polypeptide amyloïde d'îlots pancréatiques humains-(1-7)-peptidyl-  
 [11-L-arginine(K>R), 18-L-arginine(K>R)]calcitonine-1 de saumon  
 (*Oncorhynchus keta*)-(8-27)-peptidyl-polypeptide amyloïde d'îlots  
 pancréatiques humains-(33-37)-peptidamide

## davalintida

## análogo de la amilina

polipéptido amiloide de los islotes pancreáticos humanos-(1-7)-  
 peptidil-[11-L-arginina(K>R), 18-L-arginina(K>R)]calcitonina-1 de  
 salmón (*Oncorhynchus keta*)-(8-27)-peptidil-polipéptido amiloide de  
 los islotes pancreáticos humanos -(33-37)-peptidamida



H—Lys—Cys—Asn—Thr—Ala—Thr—Cys—Val—Leu—Gly—Arg—Leu—  
 Ser—Gln—Glu—Leu—His—Arg—Leu—Gln—Thr—Tyr—Pro—Arg—  
 Thr—Asn—Thr—Gly—Ser—Asn—Thr—Tyr—NH<sub>2</sub>


elinogrelum  
elinogrel

*N*-[(5-chlorothiophen-2-yl)sulfonyl]-*N'*-{4-[6-fluoro-7-(methylamino)-  
 2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phenyl}urea

## élinogrel

*N*-[(5-chlorothiophén-2-yl)sulfonyl]-*N'*-{4-[6-fluoro-7-(méthylamino)-  
 2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]phényl}urée

elinogrel

*N*-[(5-clorotiofen-2-il)sulfonil]-*N'*-{4-[6-fluoro-7-(metilamino)-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]fenil}urea $C_{20}H_{15}ClFN_5O_5S_2$ **elisidepsinun**


elisidepsin

13,8-anhidro{*N*-[(4*S*)-4-metilhexanoyl]-D-valyl-L-threonyl-L-valyl-D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothreonyl-D-alloisoleucyl-D-valyl-L-fenilalanil-(2*Z*)-2-aminobut-2-enoyl-L-valine}

élisidepsine

13,8-anhidro{*N*-[(4*S*)-4-méthylhexanoyl]-D-valyl-L-thréonyl-L-valyl-D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothréonyl-D-alloisoleucyl-D-valyl-L-phénylalanil-(2*Z*)-2-aminobut-2-énoyl-L-valine}

elisidepsina

13,8-anhidro{*N*-[(4*S*)-4-metilhexanoil]-D-valil-L-treonil-L-valil-D-valil-D-prolil-L-ornitil-D-alloisoleucil-D-alotreonil-D-alloisoleucil-D-valil-L-fenilalanil-(2*Z*)-2-aminobut-2-enoil-L-valina} $C_{75}H_{124}N_{14}O_{16}$ **elpetriginum**

elpetrigine



3-(2,3,5-trichlorophenyl)pyrazine-2,6-diamine

elpétrigine

3-(2,3,5-trichlorophényl)pyrazine-2,6-diamine

elpetrigina

3-(2,3,5-triclorofenil)pirazina-2,6-diamina



**enisamii iodidum**  
enisamium iodide



iodure d'énisamium

ioduro de enisamio

4-(benzylcarbamoyl)-1-methylpyridin-1-ium iodide

iodure de 4-(benzylcarbamoyl)-1-méthylpyridinium

ioduro de 4-(bencilcarbamoil)-1-metilpiridin-1-io



**eptacogum alfa pegolum (activatum) #**  
eptacog alfa pegol (activated)


eptacog alfa pégol (activé)

eptacog alfa pegol (activado)

pegylated human coagulation factor VII, activated blood-coagulation factor VII (EC 3.4.21.21, serum prothrombin conversion accelerator), human factor VII light chain (135-262)-disulfide with human factor VII heavy chain, some sialyl units of the *N*-linked carbohydrates are mono-*O*-[ $\alpha$ -methylpoly(oxyethylene) hydrogen phosphate] esterified (average value of the ratio factor VII/pegol is close to 1)

facteur VII humain de la coagulation pégylé, activé  
facteur VII de la coagulation sanguine (EC 3.4.21.21, accélérateur de conversion de la prothrombine sérique), (135-262) disulfure entre la chaîne légère et la chaîne lourde du facteur VII humain, quelques unités acide *N*-acétylneuraminique de la partie *N*-glycosyl sont estérifiées, mono-*O*-[ $\alpha$ -méthylpoly(oxyéthylène) hydrogénophosphate] (rapport facteur VII/pegol voisin de 1)

factor VII de coagulación humano pegilado, activado  
factor VII de coagulación sanguínea (EC 3.4.21.21, acelerador de conversión de la protrombina de suero), (135-262) disulfuro entre la cadena ligera y la cadena pesada del factor VII humano, algunas unidades ácido *N*-acetilneuraminico de la parte *N*-glicosilo están esterificadas, mono-*O*-[ $\alpha$ -metilpoli(oxietileno) hidrogenofosfato] (relación factor VII/pegol cercano de 1)



Light chain / Chaîne légère / Cadena ligera

ANAFLEELRP GSLEEECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50  
 ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGEQ 100  
 YCSHTGTGR SCRCHEGYSL LADGVSTPT VEYPCGKIPI LEKRNASKP 150  
 GR 152

Heavy chain / Chaîne lourde / Cadena pesada


IVGGKVCP KGECPWQVLL LVNGAQLCGG TLINTIWWVS AAHCFDKIKN 200  
 WRNLIAVLGE HDLSEHDGDE QSRRAQVVI PSTYVPGTTN HDIALRLHQ 250  
 PVVLTQDHVVP LCLPERTFSE RTLAFVRFSL VSGWGQLLDR GATALELMVL 300  
 NVPRMTQDC LQQRKVGDS PNITEYMFCA GYSDGSKDSC KGDSGGPHAT 350  
 HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV SQYIEWLQKL MRSEPRPGVL 400  
 LRAPFP 406

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

17-22 50-61 55-70 72-81 91-102 98-112  
 114-127 135-262 159-164 178-194 310-329 340-368

Modified residues / Résidus modifiés / Residuos modificados

E  
 6-7-14-16-19-20-25-26-29-35  
 4-carboxyGlu



Glycosylation sites (S, N) / Sites de glycosylation (S, N) / Posiciones de glicosilación (S, N)

Ser-52 Ser-60 Asn-145 Asn-322

(β-Xyl)<sub>n</sub>-β-Glc→S-52 α-Fuc→S-60  
 n = 0-2

R→3-β-Gal→3-β-Gl-N→2-α-Man→6  
 R'→3-β-Gal→3-β-Gl-N→2-α-Man→3 } β-Man→4-β-Gl-N→4-β-Gl-N→N

R = α-Sia, R' = α-Sia or PEG-α-Sia or R' = α-Sia, R = α-Sia or PEG-α-Sia

Fuc = 6-deoxy-L-galactopyranosyl

Gal = D-galactopyranosyl

Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl

Man = D-mannopyranosyl

PEG- = O-[α-methylpoly(oxyethylene) hydrogen phosphate]

Sia = 5-N-acetyl-α-neuramin-2-yl

Xyl = D-xylopyranosyl

etamicastatum

etamicastat



5-(2-aminoethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-  
 1,3-dihydro-2H-imidazole-2-thione

étamicastat

5-(2-aminoéthyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]-  
 1,3-dihydro-2H-imidazole-2-thione

etamicastat

5-(2-aminoetil)-1-[(3R)-6,8-difluoro-3,4-dihidro-2H-cromen-3-il]-  
 1,3-dihidro-2H-imidazol-2-tiona



**evatanepagum**


evatanepag

2-{3-[(N-{[4-(*tert*-butyl)phenyl]methyl}pyridine-3-sulfonamido)methyl]phenoxy}acetic acid

évatanépag

acide 2-{3-[(N-{[4-(*tert*-butyl)phényl]méthyl}pyridine-3-sulfonamido)méthyl]phénoxy}acétique

evatanepag

ácido 2-{3-[(N-{[4-(*terc*-butil)fenil]metil}piridina-3-sulfonamido)metil]fenoxi}acéticoC<sub>25</sub>H<sub>28</sub>N<sub>2</sub>O<sub>5</sub>S**fezakinumabum #**

fezakinumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* interleukin 22 (IL22, IL-22, ILTIF, IL-TIF)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-2\*02 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.14] (1-121) -IGHG1\*03 CH1 R120>K, CH3 K130>del (122-450)], (224-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (96.00%) -IGLJ2\*01 K123>Q) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; (230-230":233-233")-bisdisulfide dimer

fézakinumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* interleukine 22 (IL22, IL-22, ILTIF, IL-TIF)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV1-2\*02 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.14] (1-121) -IGHG1\*03 CH1 R120>K, CH3 K130>del (122-450)], (224-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (96.00%) -IGLJ2\*01 K123>Q) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dimère (230-230":233-233")-bisdisulfure

fezakinumab

inmunoglobulina G1-lambda, anti-[interleukina 22 (IL22, IL-22, ILTIF, IL-TIF) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV1-2\*02 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.14] (1-121) -IGHG1\*03 CH1 R120>K, CH3 K130>del (122-450)], (224-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40\*01 (96.00%) -IGLJ2\*01 K123>Q) [9.3.11] (1'-111') -IGLC2\*01 (112'-217')]; dímero (230-230":233-233")-bisdisulfuro

C<sub>6408</sub>H<sub>9886</sub>N<sub>1710</sub>O<sub>2016</sub>S<sub>44</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYMHWVRQA PGQGLEWVGW 50  
 INPYTGSAFY AQKFRGRVTM TRDTSISTAY MELSLRSDDD TAVYYCAREP 100  
 EKFDSDSDSV WGRGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAAALGLV 150  
 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200  
 TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250  
 PKDTLMISRT PEVTCVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300  
 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350  
 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTPP 400  
 VLDSGSGFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNY TQKSLSLSPG 450

## Light chain / Chaîne légère / Cadena ligera

QAVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYGVHWYQQ LPGTAPKLLI 50  
 YGDSNRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYIC QSYDNSLSGY 100  
 VFGGGTQLTV LGQPKAAPSV TLFPSSSEEL QANKATLVCL ISDFYPGAVT 150  
 VAWKADSSPV KAGVETTPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200  
 THEGSTVEKT VAPTECS 217

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 148-204 265-325 371-429  
 22"-96" 148"-204" 265"-325" 371"-429"  
 Intra-L 22'-90' 139'-198'  
 22'''-90''' 139'''-198'''  
 Inter-H-L 224-216' 224"-216"  
 Inter-H-H 230-230" 233-233"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

301, 301"

**filibuvirum**

filibuvir



(6*R*)-6-cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-  
 3-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-  
 5,6-dihydro-2*H*-pyran-2-one

filibuvir

(6*R*)-6-cyclopentyl-6-[2-(2,6-diéthylpyridin-4-yl)éthyl]-  
 3-[(5,7-diméthyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)méthyl]-4-hydroxy-  
 5,6-dihydro-2*H*-pyran-2-one

filibuvir

(6*R*)-6-ciclopentil-6-[2-(2,6-dietilpiridin-4-il)etil]-  
 3-[(5,7-dimetil[1,2,4]triazolo[1,5-*a*]pirimidin-2-il)metil]-4-hidroxi-  
 5,6-dihidro-2*H*-piran-2-ona

C<sub>29</sub>H<sub>37</sub>N<sub>5</sub>O<sub>3</sub>**flutemetamolium (<sup>18</sup>F)**flutemetamol (<sup>18</sup>F)2-{3-[<sup>18</sup>F]fluoro-4-(methilamino)fenil}-1,3-benzotiazol-6-olflutémétamol (<sup>18</sup>F)2-[3-[<sup>18</sup>F]fluoro-4-(méthylamino)phényl]-1,3-benzotiazol-6-olflutemetamol (<sup>18</sup>F)2-{3-[<sup>18</sup>F]fluoro-4-(metilamino)fenil}-1,3-benzotiazol-6-olC<sub>14</sub>H<sub>11</sub>[<sup>18</sup>F]N<sub>2</sub>OS

**fonturacetamum**


fonturacetam

*rac*-2-[(4*R*)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide

fonturacétam

*rac*-2-[(4*R*)-2-oxo-4-phénylpyrrolidin-1-yl]acétamide

fonturacetam

*rac*-2-[(4*R*)-4-fenil-2-oxopirrolidin-1-il]acetamidC<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>**fresolimumabum #**

fresolimumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* transforming growth factor beta (TGFB or TGFbeta or TGF-beta, including TGF-beta-1 or TGFB1, TGF-beta-2 or TGFB2 or G-TsF and TGF-beta-3 or TGFB3)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-447) [*Homo sapiens* VH (IGHV1-69\*10 (89.70%) -(IGHD)-IGHJ3\*01) [8.8.13] (1-120) -IGHG4\*01 (121-447)], (134-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (93.80%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; (226-226":229-229")-bisdisulfide dimer

frésolimumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* facteur de croissance transformant bêta (TGFB ou TGFbêta ou TGF-bêta, comprenant TGF-bêta1 ou TGFB1, TGF-bêta2 ou TGFB2 ou G-TsF et TGF-bêta3 ou TGFB3)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-447) [*Homo sapiens* VH (IGHV1-69\*10 (89.70%) -(IGHD)-IGHJ3\*01) [8.8.13] (1-120) -IGHG4\*01 (121-447)], (134-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (93.80%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimère (226-226":229-229")-bisdisulfure

fresolimumab

inmunoglobulina G4-kappa, anti-[factor de crecimiento transformador beta de *Homo sapiens* (TGFB o TGFbeta o TGF-beta, incluye TGF-beta-1 o TGFB1, TGF-beta-2 o TGFB2 o G-TsF y TGF-beta-3 o TGFB3)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-447) [*Homo sapiens* VH (IGHV1-69\*10 (89.70%) -(IGHD)-IGHJ3\*01) [8.8.13] (1-120) -IGHG4\*01 (121-447)], (134-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (93.80%) -IGKJ5\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dímero (226-226":229-229")-bisdisulfuro

C<sub>6392</sub>H<sub>9926</sub>N<sub>1698</sub>O<sub>2026</sub>S<sub>44</sub>

Heavy chain / Chaîne lourde / Cadena pesada  
QVQLVQSGAE VKKPGSSVKV SCKASGYTFS SNVISWVRQA PGQGLEWMGG 50  
VIPIVDIANY AQRFGKRVTI TADESTSTTY MELSSLRSED TAVYYCASTL 100  
GLVLDAMDYW GQGTLLTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150  
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTTK 200  
YTCNVDRHKS NTKVDKRVES KYGPPCPSCP APEFLGGPSV FLFPKPKDT 250  
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300  
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350  
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVVLD 400  
DGSFFLYSRL TVDKSRWQEG NVFSCSVME ALHNHYTQKS LSLSLGK 447

Light chain / Chaîne légère / Cadena ligera  
ETVLTQSPGT LSLSPGERAT LSCRASQSLG SSYLAWYQQK PGQAPRLLIY 50  
GASSRAPGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYADSPITFG 100  
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150  
VDNALQSGNS QESVTEQDSK DSTYSLSTL TSKADYEKH KVAACEVTHQ 200  
GLSSPVTKSF NRGEK 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
Intra-H 22-96 147-203 261-321 367-425  
22"-96" 147"-203" 261"-321" 367"-425"  
Intra-L 23'-89' 135'-195'  
23"-89" 135"-195"  
Inter-H-L 134-215' 134"-215"  
Inter-H-H 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
297, 297"

**girentuximabum #**  
girentuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* carbonic anhydrase IX (CAIX, CA9, MN, G250)], chimeric monoclonal antibody;  
gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

girentuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* anhydrase carbonique IX (CAIX, CA9, MN, G250)], anticorps monoclonal chimérique;  
chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

girentuximab

inmunoglobulina G1-kappa, anti-[anhidrasa carbónica IX de *Homo sapiens* (CAIX, CA9, MN, G250)], anticuerpo monoclonal quimérico;  
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

C<sub>6460</sub>H<sub>10006</sub>N<sub>1718</sub>O<sub>2018</sub>S<sub>48</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

DVKLVESGGG LVKLGGSLKL SCAASGFTFS NYMSWVRQT PEKRLELVAA 50  
 INSDGGITYY LDTVKGRTI SRDNAKNTLY LQMSSLKSED TALFYCARHR 100  
 SGYFMSMDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150  
 YFPEPVTVSW NSGALTSGVH TFFAVLQSSG LYSLSVVTV PSSSLGTQTY 200  
 ICNVNHPKPSN TKVDKKVEPK SCDKTHTCP CPAPELLGGP SVFLFPPKPK 250  
 DTLMISRTPV VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300  
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350  
 YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPPVL 400  
 DSDGSFFLYS KLTVDKSRWQ QGNVFCSCVM HEALHNHYTQ KSLSLSPGK 449

## Light chain / Chaîne légère / Cadena ligera

DIVMTQSQRF MSTTVGDRVS ITCKASQNVV SAVAWYQKQP GQSPKLLIYS 50  
 ASNRYTGVPD RFTGSGSGTD FTLTISNMQS EDLADFFCQQ YSNYPWTFGG 100  
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150  
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200  
 LSSPVTKSFN RGEC 214

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 263-323 369-427  
 22"-96" 146"-202" 263"-323" 369"-427"

Intra-L 23'-88' 134'-194'  
 23'''-88''' 134'''-194'''

Inter-H-L 222-214' 222"-214"  
 Inter-H-H 228-228" 231-231"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

**gisadenafilum**

gisadenafil


5-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]pyridin-3-yl}-3-ethyl-2-(2-methoxyethyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

gisadénafil

5-{2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]pyridin-3-yl}-3-éthyl-2-(2-méthoxyéthyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

gisadenafilo

3-etil-5-{5-[(4-etilpiperazin-1-il)sulfonil]-2-etoxipiridin-3-il}-2-(2-metoxietil)-2,6-dihidro-7H-pirazolo[4,3-d]pirimidin-7-ona

C<sub>23</sub>H<sub>33</sub>N<sub>7</sub>O<sub>5</sub>S**givinostatium**

givinostat



{6-[(diethylamino)methyl]naphthalen-2-yl}methyl 4-(hydroxycarbamoyl)phenyl]carbamate

givinostat

4-(hydroxycarbamoyl)phényl]carbamate de {6-[(diéthylamino)méthyl]naphtalén-2-yl}méthyle

givinostat

4-(hidroxicarbamoi)fenil]carbamato de {6-[(dietilamino)metil]naftalen-2-il}metilo

**golnerminogenum pradenovecum #**

golnerminogene pradenovec

a replication deficient human adenovirus 5 viral vector deleted in the E1, E4 and part of the E3 region and expressing a human tumour necrosis factor alpha (TNF- $\alpha$ ) gene inserted in the E1 region and under the control of an Egr-1 promoter and the SV40 polyadenylation sequence

golnerminogène pradénovec

vecteur viral adénovirus humain 5 sans capacité de réplication, dont les régions E1, E4 et une partie de la région E3 ont été supprimées, et exprimant un gène humain du facteur de nécrose tumorale alpha (TNF- $\alpha$ ) inséré dans la région E1 et sous le contrôle d'un promoteur Egr-1 et la séquence de polyadénylation SV40

golnerminogén pradenovec

vector viral adenovirus humano 5 sin capacidad de replicación con delección de E1, E4 y parte de la región E3 y que expresa un gen humano del factor de necrosis tumoral alfa (TNF- $\alpha$ ) insertado en la región E1 y bajo control de un promotor Egr-1 y la secuencia de poliadenilación de SV40

**gosogliptinum**

gosogliptin



(3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)piperazin-1-yl]pyrrolidin-2-yl}methanone

gosogliptine

(3,3-difluoropyrrolidin-1-yl){(2S,4S)-4-[4-(pyrimidin-2-yl)pipérazin-1-yl]pyrrolidin-2-yl}méthanone

gosogliptina

(3,3-difluoropirrolidin-1-il){(2S,4S)-4-[4-(pirimidin-2-il)piperazin-1-il]pirrolidin-2-il}metanona

**imagabalinum**

imagabalin



(3S,5R)-3-amino-5-methyloctanoic acid

imagabaline

acide (3S,5R)-3-amino-5-méthyloctanoïque

imagabalina

ácido (3S,5R)-3-amino-5-metiloctanoico



**imetelstatum**

imetelstat


3'-amino-3'-deoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-3'-deoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-3'-deoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thiocytidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadenylyl-(3'→5')-3'-amino-2',3'-dideoxyadenosine 5'-{O-[2-hydroxy-3-(hexadecanoylamino)propyl] hydrogen phosphorothioate}

imételstat

5'-{O-[2-hydroxy-3-(hexadécanoylamino)propyl] hydrogénophosphorothioate} de 3'-amino-3'-déoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-3'-déoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-3'-déoxy-*P*-thiothymidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioguanilyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thiocytidylyl-(3'→5')-3'-amino-2',3'-dideoxy-*P*-thioadénylyl-(3'→5')-3'-amino-2',3'-dideoxyadénosine

imetelstat

5'-{O-[2-hidroxi-3-(hexadecanoilamino)propil] hidrógenofosforotioato} de 3'-amino-3'-desoxi-*P*-tiotimidilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-3'-desoxi-*P*-tiotimidilil-(3'→5')-3'-amino-3'-desoxi-*P*-tiotimidilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioguanilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tiocitidilil-(3'→5')-3'-amino-2',3'-didesoxi-*P*-tioadenilil-(3'→5')-3'-amino-2',3'-didesoxiadenosina

C<sub>148</sub>H<sub>211</sub>N<sub>68</sub>O<sub>53</sub>P<sub>13</sub>S<sub>13</sub>(3'-5')d(3'-amino-3'-deoxy-*P*-thio)(-pT-A-G-G-G-T-T-A-G-A-C-A-A)**insulinum degludecum**

insulin degludec


*N*<sup>6,B29</sup>-[*N*<sup>2</sup>-(15-carboxypentadecanoyl)-L-γ-glutamyl]-des-B30-L-threonine-insulin human

insuline dégludec

*N*<sup>6,B29</sup>-[*N*<sup>2</sup>-(15-carboxypentadécanoyl)-L-γ-glutamyl]-dés-B30-L-thréonine-insuline humaine

insulina degludec

*N*<sup>6,B29</sup>-[*N*<sup>2</sup>-(15-carboxipentadecanoil)-L-γ-glutamyl]-des-B30-L-treonina-insulina humana

C<sub>274</sub>H<sub>411</sub>N<sub>65</sub>O<sub>81</sub>S<sub>6</sub>

**intetumumabum #**

intetumumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* integrin alpha-V (CD51, ITGAV, subunit of alphaV-beta3 or CD51/CD61 or vitronectin receptor or VNR, subunit of alphaV-beta5)], *Homo sapiens* monoclonal antibody;  
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-30\*01 (91.80%) -(IGHD)-IGHJ3\*02) [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ3\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer

intétumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* intégrine alpha-V (CD51, ITGAV, sous-unité de alphaV-bêta3 ou CD51/CD61 ou récepteur de la vitronectine ou VNR, sous-unité de alphaV-bêta5)], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV3-30\*01 (91.80%) -(IGHD)-IGHJ3\*02) [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ3\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure

intetumumab

inmunoglobulina G1-kappa, anti-[integrina alfa-V de *Homo sapiens* (CD51, ITGAV, subunidad de alfaV-beta3 o CD51/CD61 o receptor de la vitronectina o VNR, subunidad de alfaV-beta5)], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-30\*01 (91.80%) -(IGHD)-IGHJ3\*02) [8.8.12] (1-119) -IGHG1\*01 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (100.00%) -IGKJ3\*01) [6.3.10] (1'-108')-IGKC\*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro

C<sub>6468</sub>H<sub>10008</sub>N<sub>1744</sub>O<sub>2006</sub>S<sub>40</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGSRRL SCAASGFTFS RYTMHWVRQA PGKGLEWVAV 50
ISFDGSKYY VDSVKGRFTI SRDSENTLY LQVNILRAED TAVYYCAREA 100
RGSYAFDIWG QGTMTVTSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTWSW NSGALTSGVH TFPAPLQSSG LYSLSVTVV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKEPK SCDDKTHCTCP CPAPELLGPP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPOV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
```

## Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50
ASNRATGIPA RFSGSGSGTD FTLTISLEP EDFAVYYCQQ RSNWPPFTFG 100
PGTKVDIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSTL TSKADYEK KVAACEVTHQ 200
GLSSPVTKSF NRGEK 215
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 146-202 263-323 369-427
        22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-88' 135'-195'
        23'''-88''' 135'''-195'''
Inter-H-L 222-215' 222"-215"
Inter-H-H 228-228" 231-231"
```

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

**iodum (<sup>124</sup>I) girentuximabum #**  
 iodine (<sup>124</sup>I) girentuximab


immunoglobulin G1-kappa, anti-[*Homo sapiens* carbonic anhydrase IX (CAIX, CA9, MN, G250)], chimeric monoclonal antibody radiolabeled with iodine-124;  
 gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer covalently linked to iodine-124

iodine (<sup>124</sup>I) girentuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* anhydrase carbonique IX (CAIX, CA9, MN, G250)], anticorps monoclonal chimérique marqué à l'iode 124;  
 chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure lié de façon covalente à de l'iode 124

iodine (<sup>124</sup>I) girentuximab

inmunoglobulina G1-kappa, anti-[anhidrasa carbónica IX de *Homo sapiens* (CAIX, CA9, MN, G250)], anticuerpo monoclonal quimérico marcado con iodo 124;  
 cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV5-6-2\*01 - (IGHD)-IGHJ4\*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1\*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV6-13\*01 -IGKJ1\*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC\*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro covalentemente ligado con iodo 124



Heavy chain / Chaîne lourde / Cadena pesada

|            |            |             |            |            |     |
|------------|------------|-------------|------------|------------|-----|
| DVKLVESGGG | LVKLGGSLLK | SCAASGFTFS  | NYMSWVRQT  | PEKRLVLAA  | 50  |
| INSDGGITYY | LDTVKGRFTI | SRDIAKNTLY  | LQMSSLSKSD | TALFYCARHR | 100 |
| SGYFSDMYWG | QGTSTVTSSA | STKGPSVFPL  | APSSKSTSGG | TAALGCLVKD | 150 |
| YFPEPVTVSW | NSGALTSVGH | TFFAVLQSSG  | LYSLSSVTV  | PSSSLGTQTY | 200 |
| ICNVNHPSPN | TKVKKVEPK  | SCDKTHTCPP  | CPAPELLGGP | SVFLFPKPK  | 250 |
| DTLMISRTP  | ETCVVVDVSH | EDPEVKFNWY  | VDGVEVHNAK | TKPREEQYNS | 300 |
| TYRVVSVLTV | LHQDNLNGKE | YKCKVSNKAL  | PAPIEKTISK | AKGQPREPQV | 350 |
| YTLPPSRDEL | TKNQVSLTCL | VKGFPYPSDIA | VEWESNGQPE | NNYKTTTPVL | 400 |
| DSGGSFFLYS | KLTVDKSRWQ | QGNVFSCSVM  | HEALHNHYTQ | KSLSLSPGK  | 449 |

Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| DIVMTQSQR  | FSTTVGDRVS | ITCKASQNVV | SAVAWYQQK  | GPSPKLLIYS | 50  |
| ASNRYTGVPD | RFTGSGSGTD | FTLTISNMQS | EDLADFFCQ  | YSNYPWTFGG | 100 |
| GTKLEIKRTV | AAPSVFIFPP | SDEQLKSGTA | SVVCLLNIFY | PREAKVQWKV | 150 |
| DNALQSGNSQ | ESVTEQDSKD | STYLSSTLT  | LSKADYEKHK | VYACEVTHQG | 200 |
| LSPPVTKSFN | RGEC       |            |            |            | 214 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|           |             |               |           |           |
|-----------|-------------|---------------|-----------|-----------|
| Intra-H   | 22-96       | 146-202       | 263-323   | 369-427   |
|           | 22"-96"     | 146"-202"     | 263"-323" | 369"-427" |
| Intra-L   | 23'-88'     | 134'-194'     |           |           |
|           | 23'''-88''' | 134'''-194''' |           |           |
| Inter-H-L | 222-214'    | 222"-214"     |           |           |
| Inter-H-H | 228-228"    | 231-231"      |           |           |


N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
 299, 299"

**isopropylis turofexoras**  
turofexorate isopropylpropan-2-yl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-*b*]indole-5-carboxylate

isopropyl de turofexorate

3-(3,4-difluorobenzoyl)-1,1-diméthyl-1,2,3,6-tétrahydroazépino[4,5-*b*]indole-5-carboxylate de propan-2-yle


turofexorato de isopropilo

3-(3,4-difluorobenzoyl)-1,1-dimetil-1,2,3,6-tetrahydroazepino[4,5-*b*]indol-5-carboxilato de propan-2-ilo $C_{25}H_{24}F_2N_2O_3$ **lagociclovirum**  
lagociclovir2-amino-9-(2,3-dideoxy-3-fluoro-β-D-erythro-pentofuranosyl)-1,9-dihydro-6*H*-purin-6-on

lagociclovir

2-amino-9-(2,3-didéoxy-3-fluoro-β-D-érythro-pentofuranosyl)-1,9-dihydro-6*H*-purin-6-one

lagociclovir

2-amino-9-(2,3-didesoxi-3-fluoro-β-D-eritro-pentofuranosil)-1,9-dihidro-6*H*-purin-6-ona $C_{10}H_{12}FN_5O_3$ **lebrikizumabum #**  
lebrikizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* interleukin 13 (IL13, IL-13)], humanized monoclonal antibody;  
 gamma4 heavy chain [humanized VH (*Homo sapiens* IGHV2-70\*01 (82.80%) -(IGHD)-IGHJ6\*01) [8.7.12] (1-118) -*Homo sapiens* IGHG4\*01 hinge S10>P (119-445)], (132-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1\*01 (79.20%) -IGKJ4\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; (224-224":227-227")-bisdisulfide dimer

## lébrikizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* interleukine 13 (IL13, IL-13)], anticorps monoclonal humanisé;  
chaîne lourde gamma4 [VH humanisé (*Homo sapiens* IGHV2-70\*01 (82.80%) -(IGHD)-IGHJ6\*01) [8.7.12] (1-118) -*Homo sapiens* IGHG4\*01 charnière S10>P (119-445)], (132-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1\*01 (79.20%) -IGKJ4\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dimère (224-224":227-227")-bisdisulfure

## lebrikizumab

inmunoglobulina G4-kappa, anti-[interleukina 13 de *Homo sapiens* (IL13, IL-13)], anticuerpo monoclonal humanizado;  
cadena pesada gamma4 [VH humanizada (*Homo sapiens* IGHV2-70\*01 (82.80%) -(IGHD)-IGHJ6\*01) [8.7.12] (1-118) -*Homo sapiens* IGHG4\*01 bisagra S10>P (119-445)], (132-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1\*01 (79.20%) -IGKJ4\*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC\*01 (112'-218')]; dímero (224-224":227-227")-bisdisulfuro

C<sub>6434</sub>H<sub>9972</sub>N<sub>1700</sub>O<sub>2034</sub>S<sub>50</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| QVTLRESGPA | LVKPTQTLTL | TCTVSGFSL  | AYSVNWIRQP | PGKALEWLAM | 50  |
| INGDGKIVYN | SALKSRLTIS | KDTSKNQVVL | TMTNMDPVD  | ATYYCAGDGY | 100 |
| YPYAMDNWQ  | GSLVTSSAS  | TKGPSVFPLA | PCSRSTSEST | AALGCLVKDY | 150 |
| FFEPVTVSWN | SGALTSGVHT | FPAVLQSSGL | YSLSSVVTVP | SSSLGTKTYT | 200 |
| CNVDHKPSNT | KVDKRVESKY | GPPCPPCPAP | EFLGGPSVFL | FPPKPKDTLM | 250 |
| ISRTPEVTCV | VVDVSQEDPE | VQFNWYVDGV | EVHNAKTKPR | EEQFNSTYRV | 300 |
| VSVLTVLHQD | WLNKEYKCK  | VSNKGLPSSI | EKTISKAKGQ | PREPQVYTL  | 350 |
| PSQEEMTKNQ | VSLTCLVKGF | YPSDIAVEWE | SNGQPENNYK | TTPPVLDSDG | 400 |
| SFFLYSRLTV | DKSRWQEGNV | FSCVMHEAL  | HNHYTQKSLS | LSLGK      | 445 |

## Light chain / Chaîne légère / Cadena ligera

|             |            |            |            |            |     |
|-------------|------------|------------|------------|------------|-----|
| DIVMTQSPDS  | LSVSLGERAT | INCRASKSVD | SYGNSFMHWY | QQKPGQPPKL | 50  |
| LIYLASNLES  | GVPDRFSGSG | SGTDFTLTIS | SLQAEDVAVY | YCQQNNEDPR | 100 |
| TFGGGTKEVEI | KRTVAAPSVF | IFPPSDEQLK | SGTASVVCCL | NNFYPREAKV | 150 |
| QWKVDNALQS  | GNSQESVTEQ | DSKDSSTYLS | STTLTKADY  | EKHVKYACEV | 200 |
| THQGLSSPVT  | KSFNRGEC   |            |            |            | 218 |

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|           |             |               |           |           |
|-----------|-------------|---------------|-----------|-----------|
| Intra-H   | 22-95       | 145-201       | 259-319   | 365-423   |
|           | 22"-95"     | 145"-201"     | 259"-319" | 365"-423" |
| Intra-L   | 23'-92'     | 138'-198'     |           |           |
|           | 23'''-92''' | 138'''-198''' |           |           |
| Inter-H-L | 132-218'    | 132"-218"     |           |           |
| Inter-H-H | 224-224"    | 227-227"      |           |           |

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

295, 295"

## lersivirinum

## lersivirine

5-[[3,5-diethyl-1-(2-hydroxyethyl)-1*H*-pyrazol-4-yl]oxy]benzene-1,3-dicarbonitrile


## lersivirine

5-[[3,5-diéthyl-1-(2-hydroxyéthyl)-1*H*-pyrazol-4-yl]oxy]benzène-1,3-dicarbonitrile

## lersivirina

5-[[3,5-dietil-1-(2-hidroxietyl)-1*H*-pirazol-4-il]oxi]benceno-1,3-dicarbonitrilo

C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>



**levomequitazinum**


levomequitazine

10-[[[(3*S*)-1-azabicyclo[2.2.2]octan-3-yl]methyl]-10*H*-phenothiazine

lévoméquitazine

10-[[[(3*S*)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10*H*-phénothiazine

levomequitazina

10-[[[(3*S*)-1-azabíciclo[2.2.2]octan-3-il]metil]-10*H*-fenotiazina $C_{20}H_{22}N_2S$ **litronesibum**


litronesib

(-)-*N*-{4-(2,2-dimethylpropanoyl)-5-[[2-(ethylamino)ethanesulfonamido]methyl]-5-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl}-2,2-dimethylpropanamide

litronésib

(-)-*N*-{4-(2,2-diméthylpropanoïl)-5-[[2-(éthylamino)éthanesulfonamido]méthyl]-5-phényl-4,5-dihydro-1,3,4-thiadiazol-2-yl}-2,2-diméthylpropanamide

litronesib

(-)-*N*-{4-(2,2-dimetilpropanoïl)-5-[[2-(etilamino)etanosulfonamido]metil]-5-fenil-4,5-dihidro-1,3,4-tiadiazol-2-il}-2,2-dimetilpropanamida $C_{23}H_{37}N_5O_4S_2$ 

or enantiomer  
(-)-isomer  
ou énantiomère  
(-)-isomère  
o enantiómero  
(-)-isómero

**lomitapidum**


lomitapide

*N*-(2,2,2-trifluoroethyl)-9-(4-{4-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]piperidin-1-yl}butyl)-9*H*-fluorene-9-carboxamide

lomitapide

*N*-(2,2,2-trifluoroéthyl)-9-(4-{4-[4'-(trifluorométhyl)[1,1'-biphényl]-2-carboxamido]pipéridin-1-yl}butyl)-9*H*-fluorène-9-carboxamide

lomitapida

*N*-(2,2,2-trifluoroetil)-9-(4-{4-[4'-(trifluorometil)[1,1'-bifenil]-2-carboxamido]piperidin-1-il}butil)-9*H*-fluoreno-9-carboxamida $C_{39}H_{37}F_6N_3O_2$ 

**losmapimodum**


losmapimod

6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-  
*N*-(2,2-dimethylpropyl)pyridine-3-carboxamide

losmapimod

6-[5-(cyclopropylcarbamoyl)-3-fluoro-2-méthylphényl]-  
*N*-(2,2-diméthylpropyl)pyridine-3-carboxamide

losmapimod

6-[5-(ciclopropilcarbamoil)-3-fluoro-2-metilfenil]-  
*N*-(2,2-dimetilpropil)piridina-3-carboxamidaC<sub>22</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>2</sub>**miravirsenum**

miravirsén


*all-P-ambo*-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-  
deoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioadenylyl-  
(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*,4'-*C*-  
methylene-*P*-thioguanilyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-  
*P*-thiouridylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-  
*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-  
(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-  
methylene-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-5-methyl-  
2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-  
methylene-*P*-thiocytidine

miravirsén


*all-P-ambo*-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-(3'→5')-2'-  
déoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-méthylène-*P*-thioadénylyl-  
(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*,4'-*C*-  
méthylène-*P*-thioguanilyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-  
*P*-thiouridylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-  
*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-  
(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-  
méthylène-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-5-méthyl-  
2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-  
méthylènecytidine

miravirsén

*todo-P-ambo*-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-2'-  
desoxi-*P*-tiocitidilil-(3'→5')-2'-*O*,4'-*C*-metileno-*P*-tioadenilil-(3'→5')-*P*-  
tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*,4'-*C*-metileno-  
*P*-tioguanilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiouridilil-(3'→5')-2'-  
desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-5-metil-2'-  
*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-5-  
metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-5-  
metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-5-metil-2'-*O*,4'-*C*-  
metileno-*P*-tiocitidina



(3'-5')(P-thio)(mC-dC-A-dT-dT-G-T-dC-dA-mC-dA-mC-dT-mC-mC)

**mocetinostat**

mocetinostat



*N*-(2-aminophenyl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzamide

mocétinostat

*N*-(2-aminophényl)-4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}méthyl)benzamide

mocetinostat

*N*-(2-aminofenil)-4-({[4-(piridin-3-il)pirimidin-2-il]amino}metil)benzamida

**modithromycinum**

modithromycin



*N*-[(1*R*,2*R*,3*R*,6*R*,8*R*,9*R*,10*R*,13*E*,16*S*,17*E*,18*R*)-3-ethyl-2-hydroxy-2,6,8,10,16,18-tétraméthyl-5,7-dioxy-13-{{[6-(1*H*-pyrazol-1-yl)pyridin-3-yl]méthoxyimino}-9-{{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo-hexopyranosyl]oxy}-4,11,15-trioxabicyclo[8.5.4]nonadecane-17-ylidène]acétamide

modithromycine

*N*-[(1*R*,2*R*,3*R*,6*R*,8*R*,9*R*,10*R*,13*E*,16*S*,17*E*,18*R*)-3-éthyl-2-hydroxy-2,6,8,10,16,18-tétraméthyl-5,7-dioxy-13-{{[6-(1*H*-pyrazol-1-yl)pyridin-3-yl]méthoxyimino}-9-{{[3,4,6-tridéoxy-3-(diméthylamino)-β-D-xylo-hexopyranosyl]oxy}-4,11,15-trioxabicyclo[8.5.4]nonadéc-17-ylidène]acétamide

moditromicina

*N*-[(1*R*,2*R*,3*R*,6*R*,8*R*,9*R*,10*R*,13*E*,16*S*,17*E*,18*R*)-3-etil-2-hidroxi-2,6,8,10,16,18-hexametil-5,7-dioxy-13-{{[6-(1*H*-pirazol-1-il)piridin-3-il]metoksiimino}-9-{{[3,4,6-tridesoxi-3-(dimetilamino)-β-D-xilo-hexopiranosil]oxi}-4,11,15-trioxabicyclo[8.5.4]nonadecane-17-ilidene]acetamido

**naluzotanum**

naluzotan


*N*-(3-{4-[4-(1-cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide

naluzotan

*N*-(3-{4-[4-(1-cyclohexylméthanesulfonamido)butyl]pipérazin-1-yl}phényl)acétamide

naluzotán

*N*-(3-{4-[4-(1-ciclohexilmetanosulfonamido)butil]piperazin-1-il}fenil)acetamida

**nelotanserinum**

nelotanserine


1-[3-(4-bromo-1-methyl-1*H*-pyrazol-5-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea

nélotansérine

1-[3-(4-bromo-1-méthyl-1*H*-pyrazol-5-yl)-4-méthoxyphényl]-3-(2,4-difluorophényl)urée

nelotanserina

1-[3-(4-bromo-1-metil-1*H*-pirazol-5-il)-4-metoxifenil]-3-(2,4-difluorofenil)urea



**ocriplasminum #**

ocriplasmin

truncated human plasmin:

human plasmin heavy chain A-(543-561)-peptide (548-666;558-566)-bisdisulfide with human plasmin light chain B

ocriplasmine

plasmine humaine tronquée :

chaîne lourde A de la plasmine humaine-(543-561)-peptide (548-666;558-566)-bisdisulfure avec la chaîne légère B de la plasmine humaine

ocriplasmina

plasmina humana truncada:

cadena pesada A de la plasmina humana-(543-561)-péptido (548-666;558-566)-bisdisulfuro con la cadena ligera B de la plasmina humana

 $C_{1214}H_{1890}N_{338}O_{348}S_{14}$ 

Truncated heavy chain / Chaîne lourde tronquée/ Cadena pesada truncada

|            |   |          |     |
|------------|---|----------|-----|
| PQVEPKKCPG | R | APSFDCGK | 550 |
|            |   |          | 561 |

Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |
|------------|------------|------------|------------|------------|
| VVGCCVAHP  | HSWPQVSLR  | TRFGMHFCGG | TLISPEWVLT | 600        |
| AAHCLEKSPR | PSSYKVILGA | HQEVNLEPHV | QEIEVSRFL  | EPTRKDIAL  |
| KLSSPAVITD | KVIPACLPSP | NYVADRTEC  | FITGWGETQG | TFGAGLLKEA |
| QLPVIENKVC | NRYEFLNGRV | QSTELCAGHL | AGGTDSCQGD | SGGPLVCFEK |
| DKYILQGVTS | WGLGCARPKN | PGVYVRVSRF | VTWIEGVMRN | N          |
|            |            |            |            | 791        |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
548-666 558-566 588-604 680-747 710-726 737-765**olodaterolum**


olodaterol

6-hydroxy-8-[(1*R*)-1-hydroxy-2-[[1-(4-methoxyphenyl)-1,1-diméthyléthyl]amino]éthyl]-2*H*-1,4-benzoxazin-3(4*H*)-one

olodatérol

6-hydroxy-8-[(1*R*)-1-hydroxy-2-[[2-(4-méthoxyphényl)-1,1-diméthyléthyl]amino]éthyl]-2*H*-1,4-benzoxazin-3(4*H*)-one

olodaterol

6-hidroxi-8-[(1*R*)-1-hidroxi-2-[[1-(4-metoxifenil)-2-metilpropan-2-il]amino]etil]-2*H*-1,4-benzoxazin-3(4*H*)-ona $C_{21}H_{26}N_2O_5$ **razupenemum**

razupenem



(4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-3-({4-[(5*S*)-5-méthyl-2,5-dihydro-1*H*-pyrrol-3-yl]-1,3-thiazol-2-yl}sulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylic acid

razupénem

acide (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-3-({4-[(5*S*)-5-méthyl-2,5-dihydro-1*H*-pyrrol-3-yl]thiazol-2-yl}sulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

razupenem

ácido (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hidroxietil]-4-metil-3-({4-[(5*S*)-5-metil-2,5-dihidro-1*H*-pirrol-3-il]-1,3-tiazol-2-il}sulfanil)-7-oxo-1-azabicio[3.2.0]hept-2-eno-2-carboxílico

**ridaforolimusum**

ridaforolimus


(1*R*,2*R*,4*S*)-4-[(2*R*)-2-  
 {(3*S*,6*R*,7*E*,9*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-  
 9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-  
 1,5,11,28,29-pentaoxo-  
 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,  
 34 a-tetracosahydro-3*H*-23,27-epoxy-pyrido[2,1-  
 c][1,4]oxaazacyclohentricosin-3-yl}propyl]-2-methoxycyclohexyl  
 dimethylphosphinate

ridaforolimus

(1*R*,9*S*,12*S*,15*R*,16*E*,18*R*,19*R*,21*R*,23*S*,24*E*,26*E*,28*E*,30*S*,32*S*,35*R*)  
 -12-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-[(diméthylphosphinoyl)oxy]-  
 3-méthoxycyclohexyl]-1-méthyléthyl]-1,18-dihydroxy-  
 19,30-diméthoxy-15,17,21,23,29,35-hexaméthyl-11,36-dioxa-  
 4-azatricyclo[30.3.1.0<sup>4,9</sup>]hexatriaconta-16,24,26,28-tétraène-  
 2,3,10,14,20-pentone

ridaforolimus

(1*R*,2*R*,4*S*)-4-[(2*R*)-2-  
 {(3*S*,6*R*,7*E*,9*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-  
 9,27-dihydroxy-10,21-diméthoxy-6,8,12,14,20,26-hexaméthyl-  
 1,5,11,28,29-pentaoxo-  
 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,  
 34 a-tetracosahydro-3*H*-23,27-epoxy-pyrido[2,1-  
 c][1,4]oxaazacyclohentricosin-3-yl}propyl]-2-méthoxycyclohexyl  
 diméthylfosfinato



**rilotumumabum #**

rilotumumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* hepatocyte growth factor (HGF, scatter factor, SF, hepatopoietin A)], *Homo sapiens* monoclonal antibody;

gamma2 heavy chain (1-446) [*Homo sapiens* VH (IGHV4-59\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.7.14] (1-120) -IGHG2\*01 (121-446)], (134-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15\*01 (96.80%) -IGKJ5\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; (222-222":223-223":226-226":229-229")-tetradisulfide dimer

rilotumumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* facteur de croissance de l'hépatocyte (HGF, facteur dispersant, SF, hépatopoïétine A)], *Homo sapiens* anticorps monoclonal;

chaîne lourde gamma2 (1-446) [*Homo sapiens* VH (IGHV4-59\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.7.14] (1-120) -IGHG2\*01 (121-446)], (134-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15\*01 (96.80%) -IGKJ5\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (222-222":223-223":226-226":229-229")-tétradisulfure

rilotumumab

inmunoglobulina G2-kappa, anti-[factor de crecimiento de hepatocitos de *Homo sapiens* (HGF, factor dispersante, SF, hepatopoyetina A)], anticuerpo monoclonal de *Homo sapiens* ;

cadena pesada gamma2 (1-446) [*Homo sapiens* VH (IGHV4-59\*01 (96.90%) -(IGHD)-IGHJ4\*01) [8.7.14] (1-120) -IGHG2\*01 (121-446)], (134-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15\*01 (96.80%) -IGKJ5\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dímero (222-222":223-223":226-226":229-229")-tetradisulfuro

C<sub>6464</sub>H<sub>9932</sub>N<sub>1708</sub>O<sub>2010</sub>S<sub>46</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSSETLSL TCTVSGGSIS IYYWSWIRQP PGKGLEWIGY 50
VYYSGSTNIN PSLKSRVTIS VDTSKNQFSL KLSVTAADT AVYYCARGGY 100
DFWSGYFDYW GQGLTVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSNFGTQT 200
YTCNVDHKPS NTKVDKTVR KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNGKLPAP IEKTISKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTTPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMEHA LHNHYTQKSL SLSPGK 446
```

## Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSDV SNLAWYRQKP GQAPRLIIYG 50
ASTRATGIPA RFSGSGSGTE FTLTISLQSE EDFAVYYCQQ YINWPPITFG 100
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSLSSTL TSKADYEKH KVAACEVTHQ 200
GLSSPVTKSF NRGEK 215
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-95 147-203 260-320 366-424  
22"-95" 147"-203" 260"-320" 366"-424"

Intra-L 23'-88' 135'-195'  
23'''-88''' 135'''-195'''

Inter-H-L 134-215' 134"-215"

Inter-H-H 222-222" 223-223" 226-226" 229-229"

## N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

296, 296"

**rontalizumabum #**

rontalizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* interferon alpha (IFN-alpha)], humanized monoclonal antibody;  
gamma1 heavy chain [humanized VH (*Homo sapiens*IGHV3-74\*01 (76.30%) -(IGHD)-IGHJ4\*01) [8.8.10] (1-117) -*Homo sapiens*IGHG1\*03, CH1 R120>K (118-447)], (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens*IGKV1-39\*01 (83.80%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC\*01 (112'-218')]; (226-226":229-229")-bisdisulfide dimer

rontalizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* interféron alpha (IFN-alpha)], anticorps monoclonal humanisé;  
chaîne lourde gamma1 [VH humanisé (*Homo sapiens*IGHV3-74\*01 (76.30%) -(IGHD)-IGHJ4\*01) [8.8.10] (1-117) -*Homo sapiens*IGHG1\*03, CH1 R120>K (118-447)], (220-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39\*01 (83.80%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC\*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure

rontalizumab

inmunoglobulina G1-kappa, anti-[interferón alfa de *Homo sapiens* (IFN-alpha)], anticuerpo monoclonal humanizado;  
cadena pesada gamma1 [VH humanizada (*Homo sapiens*IGHV3-74\*01 (76.30%) -(IGHD)-IGHJ4\*01) [8.8.10] (1-117) -*Homo sapiens*IGHG1\*03, CH1 R120>K (118-447)], (220-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens*IGKV1-39\*01 (83.80%) -IGKJ1\*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC\*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro

C<sub>6486</sub>H<sub>9990</sub>N<sub>1722</sub>O<sub>2026</sub>S<sub>44</sub>

Heavy chain / Chaîne lourde / Cadena pesada

|             |            |            |             |             |     |
|-------------|------------|------------|-------------|-------------|-----|
| EVQLVESGGG  | LVQPGGSLRL | SCATSGYTFT | EYIIHWVRQA  | PGKGLEWVAS  | 50  |
| INPDYDITNY  | NQRFKGRFTI | SLDKSKRTAY | LQMNSLRAED  | TAVYYCASWI  | 100 |
| SDFFDYWGQG  | TLVTVSSAST | KGPSVFPLAP | SSKSTSGGTA  | ALGCLVKDYF  | 150 |
| PEPVTVSWNS  | GALTSGVHTF | PAVLQSSGLY | SLSSVVTVP   | SSLGTQTYIC  | 200 |
| NVNHKPSNTK  | VDKKVEPKSC | DKTHTCPPCP | APPELLGGPSV | FLFPPKPKDT  | 250 |
| LMISRTPEVT  | CVVVDVSHED | PEVKFNWYVD | GVEVHNAKTK  | PREPEQYNSTY | 300 |
| RVVSVLTVLH  | QDWLNGKEYK | CKVSNKALPA | PIEKTISKAK  | GQPREPQVYT  | 350 |
| LPSPREEMTK  | NQVSLTCLVK | GFYPDSIAVE | WESNGQPENN  | YKTTTPPVLD  | 400 |
| DGSFFFLYSKL | TVDKSRWQQG | NVFSCSVME  | ALHNHYTQKS  | LSLSPGK     | 447 |

Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| DIQMTQSPSS | LSASVGDRVT | ITCRASQSVS | TSSYSYMHY  | QOKPGKAPKV | 50  |
| LISYASNLES | GVPSRFGSG  | SGTDFTLTIS | SLQPEDFATY | YQHSWGIPR  | 100 |
| TFGGQTKVEI | KRTVAAPSVF | IFPPSDEQLK | SGTASVVCLL | NNFYPREAKV | 150 |
| QNKVDNALQS | NSQESVTEQ  | DSKDSYSL   | STLTLSKADY | EKHKVYACEV | 200 |
| THQGLSSPVT | KSFNRGEC   |            |            |            | 218 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|         |         |           |           |           |
|---------|---------|-----------|-----------|-----------|
| Intra-H | 22-96   | 144-200   | 261-321   | 367-425   |
|         | 22"-96" | 144"-200" | 261"-321" | 367"-425" |

|         |             |               |
|---------|-------------|---------------|
| Intra-L | 23'-92'     | 138"-198"     |
|         | 23'''-92''' | 138'''-198''' |

|           |          |            |
|-----------|----------|------------|
| Inter-H-L | 220-218' | 220"-218'" |
| Inter-H-H | 226-226" | 229-229"   |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

297, 297<sup>ii</sup>**semaglutidum**

semaglutide


N<sup>6,26</sup>-[18-[N-(17-carboxyheptadecanoyl)-L-γ-glutamyl]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl]-[8-(2-amino-2-propanoic acid),34-L-arginine]human glucagon-like peptide 1(7-37)

sémaglutide

N<sup>6,26</sup>-[18-[N-(17-carboxyheptadécanoyl)-L-γ-glutamyl]-10-oxo-3,6,12,15-tétraoxa-9,18-diazaoctadécanoyl]-[8-(acide 2-amino-2-méthylpropanoïque),34-L-arginine]peptide 1(7-37) apparenté au glucagon humain (GLP-1(7-37))

semaglutida

$N^{6,26}$ -{18-[*N*-(17-carboxiheptadecanoyl)-L-γ-glutamyl]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl}-[8-(ácido 2-amino-2-metilpropanoico),34-L-arginina]péptido 1(7-37) similar al glucagón tipo 1 humano

C<sub>187</sub>H<sub>291</sub>N<sub>45</sub>O<sub>59</sub>

serdemetanum

serdemetan


*N*-[2-(1*H*-indol-3-yl)ethyl]-*N'*-(pyridin-4-yl)benzene-1,4-diamine

serdémétan

*N*-[2-(1*H*-indol-3-yl)éthyl]-*N'*-(pyridin-4-yl)benzène-1,4-diamine

serdemetan

*N*-[2-(1*H*-indol-3-il)etil]-*N'*-(piridin-4-il)benceno-1,4-diamina

C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>

setileutonum

setileuton


4-(4-fluorophenyl)-7-[(5-[(2*S*)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl)amino)methyl]-2*H*-chromen-2-one

sétileuton

4-(4-fluorophényl)-7-[(5-[(2*S*)-1,1,1-trifluoro-2-hydroxybutan-2-yl]-1,3,4-oxadiazol-2-yl)amino)méthyl]-2*H*-chromèn-2-one

setileutón

4-(4-fluorofenil)-7-[(5-[(2*S*)-1,1,1-trifluoro-2-hidroxibutan-2-il]-1,3,4-oxadiazol-2-il)amino)metil]-2*H*-cromen-2-ona

C<sub>22</sub>H<sub>17</sub>F<sub>4</sub>N<sub>3</sub>O<sub>4</sub>

**sifalimumabum #**  
sifalimumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* interferon alpha (IFN-alpha)], *Homo sapiens* monoclonal antibody;  
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV1-18\*01 (95.90%) -(IGHD)-IGHJ4\*01) [8.8.9] (1-116) -IGHG1\*03 CH1 R120>K (117-446)], (219-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (99.00%) -IGKJ1\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; (225-225'':228-228'')-bisdisulfide dimer

## sifalimumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* interféron alpha (IFN-alpha)], *Homo sapiens* anticorps monoclonal;  
chaîne lourde gamma 1 (1-446) [*Homo sapiens* VH (IGHV1-18\*01 (95.90%) -(IGHD)-IGHJ4\*01) [8.8.9] (1-116) -IGHG1\*03 CH1 R120>K (117-446)], (219-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (99.00%) -IGKJ1\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dimère (225-225'':228-228'')-bisdisulfure

## sifalimumab

inmunoglobulina G1-kappa, anti-[interferón alfa (IFN-alfa) de *Homo sapiens*], anticuerpo monoclonal de *Homo sapiens*;  
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV1-18\*01 (95.90%) -(IGHD)-IGHJ4\*01) [8.8.9] (1-116) -IGHG1\*03 CH1 R120>K (117-446)], (219-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20\*01 (99.00%) -IGKJ1\*01) [7.3.9] (1'-108') -IGKC\*01 (109'-215')]; dímero (225-225'':228-228'')-bisdisulfuro

C<sub>6396</sub>H<sub>9922</sub>N<sub>1714</sub>O<sub>2008</sub>S<sub>42</sub>

## Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYSISWVRQA PGQGLEWMGW 50
ISVYNGNTNY AQKFQGRVTM TTDSTSTSTAY LELRSLRSD TAVVYCARDP 100
IAAGYWGQGT LVTSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSNWNG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KHTCTPPCPA PELGGPSVF LFPKPKDRTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VSVLTVLHQ DWLNGKEYKC KVSNAKLPAP IEKTISKARG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTTPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446
```

## Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS STYLAWYQOK PGQAPRLLIY 50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYVCQ QYGSSPRTFG 100
QGKTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TLISKADYEKH KVIACEVTHQ 200
GLSSPVTKSF NRGEK 215
```

## Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 143-199 260-320 366-424  
22"-96" 143"-199" 260"-320" 366"-424"  
Intra-L 23'-89' 135"-195'  
23'"-89'" 135'"-195'"  
Inter-H-L 219-215' 219"-215"  
Inter-H-H 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
296, 296"

**sonedenosonum**  
sonedenoson


2-[2-(4-chlorophenyl)ethoxy]adenosine

## sonédénoson

2-[2-(4-chlorophényl)éthoxy]-9-β-D-ribofuranosyl-9*H*-purin-6-amine

## sonedenosón

2-[2-(4-clorofenil)etoxi]adenosina

C<sub>18</sub>H<sub>20</sub>ClN<sub>5</sub>O<sub>5</sub>

**sothrombomodulinum alfa #**  
sothrombomodulin alfa

soluble mutated human thrombomodulin  
[388-leucine(M>L),456-glycine(R>G),457-glutamine(H>Q),474-alanine(S>A)]human thrombomodulin (fetomodulin, CD141)-(4-490)-peptide, glycosylated

sothrombomoduline alfa

thrombomoduline humaine soluble mutée  
[388-leucine(M>L),456-glycine(R>G),457-glutamine(H>Q),474-alanine(S>A)]thrombomoduline humaine (fetomoduline, CD141)-(4-490)-peptide, glycosylée

sotrombomodulina alfa

trombomodulina humana soluble mutada  
[388-leucina(M>L),456-glicina(R>G),457-glutamina(H>Q),474-alanina(S>A)]trombomodulina humana (fetomodulina, CD141)-(4-490)-péptido, glicosilado

C<sub>2181</sub>H<sub>3278</sub>N<sub>616</sub>O<sub>706</sub>S<sub>49</sub>

|            |            |             |             |            |     |
|------------|------------|-------------|-------------|------------|-----|
| EPQPGGSQCV | EHDCFALYPG | PATFLNASQI  | CDGLRGHLMT  | VRSSVAADVI | 50  |
| SLLLNQDGGV | GRRRLWIGLQ | LPPGCGDPKR  | LGPLRGFQWV  | TGDNNTSYSR | 100 |
| WARLDLNGAP | LCGFLCVAVS | AAEATVPSEP  | IWEEQQCEVK  | ADGFLCEHFF | 150 |
| PATCRPLAVE | PGAAAAVSI  | TYGTFPFAARG | ADFQALPVGS  | SAAVAPLGLQ | 200 |
| LMCTAPPGAV | QGHWAREAPG | AWDCSVENG   | CEHACNAIPG  | APRCQCPAGA | 250 |
| ALQADGRSCT | ASATQSCNDL | CEHFCVNPDP  | QPGSYSCMCE  | TGYRLAADQH | 300 |
| RCEDVDDCIL | EPSPCPQRCV | NTQGGFECHC  | YPNYDLVDGE  | CVEPVDPCFR | 350 |
| ANCEYQCQPL | NQTSYLCVCA | EGFAPIPHEP  | HRCQLFCNQT  | ACPADCNPNT | 400 |
| QASCECEPEY | ILDDGFICTD | IDECENGGFC  | SGVCHNLPFGT | FECICGPDPA | 450 |
| LAGQIGTDCD | SGKVDGGDSG | AGEPPPSPTP  | GSTLTTPP    |            | 487 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
Total 23 disulfide bridges in the molecule, so far only four disulfide bridge positions verified.  
23 ponts disulfure au total dans la molécule, pour le moment, seuls quatre ont été vérifiés.  
23 puentes disulfuro en el total en la molécula, por el momento, sólo cuatro han sido verificados.  
9-14 31-146 154-203 224-235

N-Glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación  
Asn-26 Asn-95 Asn-361 Asn-388

**tafamidisum**  
tafamidis



2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

tafamidis

acide 2-(3,5-dichlorophényl)-1,3-benzoxazole-6-carboxylique

tafamidis

ácido 2-(3,5-diclorofenil)-1,3-benzoxazol-6-carboxílico



**taliglucerasum alfa #**  
taliglucerase alfa

L-glutamyl-L-phenylalanyl-[495(497)-L-histidine(R>H)]human glucosylceramidase (beta-glucocerebrosidase) peptide with L-aspartyl-L-leucyl-L-leucyl-L-valyl-L-aspartyl-L-threonyl-L-methionine, glycosylated peptide 1-506

taliglucérase alfa

L-glutamyl-L-phénylalanyl-[495(497)-L-histidine(R>H)]glucosylcéramidase humaine (bêta-glucocérébrosidase) peptide avec la L-aspartyl-L-leucyl-L-leucyl-L-valyl-L-aspartyl-L-thréonyl-L-méthionine, peptide 1-506 glycosylé

taliglucerasa alfa

L-glutamyl-L-fenilalanil-[495(497)-L-histidina(R>H)]glucosilceramidasa humana (beta-glucocerebrosidasa) péptido con la L-aspartil-L-leucil-L-leucil-L-valil-L-aspartil-L-treonil-L-metionina, péptido 1-506 glicosilado




```

EFARPCIPKS  FGYSSVVCVC  NATYCDSFDP  PTFPALGTFS  RYESTRSGRR  50
MELSMGPIQA  NHTGTGLLLT  LQPEQKFQKV  KGFGGAMTDA  AALNILALSP  100
PAQNLLLSKY  FSEEGIGYNI  IRVPMASCDP  SIRTYYTADT  PDDFQLHNFS  150
LPEEDTKLKI  PLIHRALQLA  QRPVSLLASP  WTSPTWLKTN  GAVNGKGSJK  200
GQPGDIYHQT  WARYFVKFLD  AYAHHKLQFW  AVTAENEPSA  GLLSGYPFQC  250
LGFTPEHQRD  FIARDLGPTL  ANSTHHNVRL  LMLDDQRLLL  PHWAKVVLTD  300
PEAAKYVHGI  AVHWYLDFLA  PAKATLGETH  RLFPNTMLFA  SEACVGSKEW  350
EQSVRLGSWD  RGMQYSHSII  TNLLYHVVGW  TDWNLALNPE  GGPNWVRNEV  400
DSPITVDITK  DTFYKQPMFY  HLGHFSEKFI  EGSQVRGLVA  SQKNLDLAVA  450
LMHPDGSAAV  VVLNRSSKDV  PLTIKDPAVG  FLETISPGYS  IHTYLWHRQD  500
LLVDTM      506

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro  
6-18 20-25

Glycosylation sites N / Sites de glycosylation N / Posiciones de glicosilación N  
Asn-21 Asn-61 Asn-148 Asn-272



Fuc = 6-deoxy-D-galactopyranosyl  
Gl-N = 2-(acetylamino)-2-deoxy-D-glucopyranosyl  
Man = D-mannopyranosyl  
Xyl = D-xylopyranosyl

**tecarfarinum**  
tecarfarin



1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate

técarfarine

4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate de 1,1,1,3,3,3-hexafluoro-2-méthylpropan-2-yl

tecarfarina

4-[(4-hidroxi-2-oxo-2H-cromen-3-il)metil]benzoato de 1,1,1,3,3,3-hexafluoro-2-metilpropan-2-ilo



**teglarinadi chloridum**  
teglarinad chloride


4-({*N'*-[6-(4-chlorophenoxy)hexyl]})-*N''*-cyanocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecyl)pyridin-1-ium chloride

chlorure de téglarinad

chlorure de 4-({*N'*-[6-(4-chlorophénoxy)hexyl]})-*N''*-cyanocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadécyl)pyridin-1-ium

cloruro de teglarinad

cloruro de 4-({*N'*-[6-(4-clorofenoxi)hexil]})-*N''*-cianocarbamimidamido)-1-(3-oxo-2,4,7,10,13,16-hexaoxaheptadecil)piridin-1-io



**teprotumumabum #**  
teprotumumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* insulin-like growth factor 1 receptor (IGF1R, IGF-1R, IGF-1 receptor, CD221)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33\*01 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.11] (1-118) -IGHG1\*01 (119-448)], (221-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; (227-227'':230-230'')-bisdisulfide dimer

téprotumumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* récepteur du facteur de croissance 1 analogue à l'insuline (IGF1R, IGF-1R, récepteur de l'IGF-1, CD221)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33\*01 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.11] (1-118) -IGHG1\*01 (119-448)], (221-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dimère (227-227'':230-230'')-bisdisulfure

teprotumumab

inmunoglobulina G1-kappa, anti-[receptor del factor de crecimiento insulínico tipo 1 de *Homo sapiens* (IGF1R, IGF-1R, receptor del GF-1, CD221)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-33\*01 (91.80%) -(IGHD)-IGHJ2\*01) [8.8.11] (1-118) -IGHG1\*01 (119-448)], (221-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11\*01 (97.90%) -IGKJ1\*01) [6.3.10] (1'-108') -IGKC\*01 (109'-215')]; dímero (227-227'':230-230'')-bisdisulfuro

$C_{6476}H_{10012}N_{1748}O_{2000}S_{40}$

Heavy chain / Chaîne lourde / Cadena pesada

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| QVELVESGGG | VVQPGRSQRL | SCAASGFTFS | SYGMHWVRQA | PGKGLEWVAI | 50  |
| IWFDGSSTYY | ADSVRGRFTI | SRDNSKNTLY | LQMNSLRAED | TAVYFCAREL | 100 |
| GRRYFDLWGR | GTLVSVSSAS | TKGPSVFPLA | PSSKSTSGGT | AALGCLVKDY | 150 |
| FPEPVTVSWN | SGALTSGVHT | FPAVLQSSGL | YSLSSVVTVP | SSSLGTQTYI | 200 |
| CNVNHKPSNT | KVDKKVEPKS | CDKTHTCPPC | PAPELLGGPS | VFLFPPKPKD | 250 |
| TLMISRTPEV | TCVVVDVSHE | DPEVKFNWYV | DGVEVHNAKT | KPREEQYNST | 300 |
| YRVVSVLTVL | HQDWLNGKEY | KCKVSNKALP | APIEKTISKA | KGQPREPQVY | 350 |
| TLPPSRDELT | KNQVSLTCLV | KGFYPSDIAV | EWESNGQPEN | NYKTTTPPVD | 400 |
| SDGSFFLYSK | LTVDKSRWQQ | GNVFSCSVMH | EALHNYHTQK | SLSLSPGK   | 448 |

Light chain / Chaîne légère / Cadena ligera

|            |            |            |            |            |     |
|------------|------------|------------|------------|------------|-----|
| EIVLTQSPAT | LSLSPGERAT | LSCRASQSVS | SYLAWYQQKP | GQAPRLLIYD | 50  |
| ASKRATGIPA | RFSGSGSGTD | FTLTISSELP | EDFAVYYCQK | RSKWPPWTFG | 100 |
| QGTKVESKRT | VAAPSVFIFP | PSDEQLKSGT | ASVVCLLNNF | YPREAKVQWK | 150 |
| VDNALQSGNS | QESVTEQDSK | DSTYLSSTL  | TLSKADYEKH | KVYACEVTHQ | 200 |
| GLSSPVTKSF | NRGEC      |            |            |            | 215 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

|           |             |               |           |           |
|-----------|-------------|---------------|-----------|-----------|
| Intra-H   | 22-96       | 145-201       | 262-322   | 368-426   |
|           | 22"-96"     | 145"-201"     | 262"-322" | 368"-426" |
| Intra-L   | 23'-88"     | 135'-195'     |           |           |
|           | 23'''-88''' | 135'''-195''' |           |           |
| Inter-H-L | 221-215'    | 221"-215"     |           |           |
| Inter-H-H | 227-227"    | 230-230"      |           |           |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

298, 298"

**tipapkinogenum sovavicecum #**  
tipapkinogene sovavicec

an attenuated recombinant vaccinia viral vector (derived from the Modified Virus Ankara clone 33.1, MVATG33.1) containing an approximately 168 kilobasepair DNA genome encoding itself, human interleukin-2 (IL-2) and mutated-forms of the Human Papilloma Virus 16 (HPV-16) E6 and E7 antigens

tipapkinogène sovavicec

vecteur viral de la vaccine recombinant atténué (dérivé du virus modifié Ankara clone 33.1, MVATG33.1) contenant un génome ADN d'approximativement 168 kilopaires de bases se codifiant lui-même, l'interleukine 2 humaine (IL-2) et des formes mutées du papillomavirus humain 16 (HPV-16) et les antigènes E6 et E7

tipapkinogén sovavicec

vector viral vaccinia recombinante atenuado (derivado del Virus Modificado Ankara clon 33.1, MVATG33.1) contiene un DNA genómico de aproximadamente 168 kilopares de bases que codifican el propio virus, interleukina-2 (IL-2) humana y formas mutadas del Virus del papiloma humano 16 (HPV-16) y los antígenos E6 y E7

**varfolllitropinum alfa #**  
varfolllitropin alfa

[alpha,83-L-asparagine;beta,55-L-asparagine,57-L-threonine]  
folllitropin alpha (human) modified human follicle-stimulating hormone:  
heterodimer of [83-L-asparagine(H>N)]human glycoprotein hormones alpha chain (FSH-alpha) and [55-L-asparagine(E>N), 57-L-threonine(V>T)]human folllitropin subunit beta (FSH-beta), glycosylated

varfolllitropine alfa

[alpha,83-L-asparagine;bêta,55-L-asparagine,57-L-thréonine]  
folllitropine alpha (humaine) hormone stimulante du follicule de De Graaf humaine modifiée :  
hétérodimère constitué de la [83-L-asparagine(H>N)]chaîne alpha de la glycoprotéine des hormones humaines (FSH-alpha) et de la [55-L-asparagine(E>N),57-L-thréonine(V>T)]sous-unité bêta de la folllitropine humaine (FSH-bêta) glycosylées

## varfolitropina alfa

[alfa,83-L-asparagina;beta,55-L-asparagina,57-L-treonina] folitropina alfa (humana) hormona estimulante del foliculo de De Graaf humana modificada :

heterodimero constituido por la [83-L-asparagina(H>N)]cadena alfa de la glicoproteína de las hormonas humanas (FSH-alfa) y de la [55- L-asparagina(E>N),57-L-treonina(V>T)]subunidad beta de la folitropina humana (FSH-beta) glicosiladas

$C_{971}H_{1511}N_{267}O_{306}S_{26}$

Alpha subunit / Sous-unité alpha / Subunidad alfa

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSTRAYTP LRSKKTMLVQ 50  
KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACNCSTCYH KS 92

Beta subunit / Sous-unité bêta / Subunidad beta

NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPAPKIQKT 50'  
CTFKNLTYET VRVPGCAHHA DSYTYPVAT QCHCGKCDSD STDCTVRGLG 100'  
PSYCSFGEMK E 111'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

7-31 10-60 28-82 32-84 59-87  
3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

N-Glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

Asn-7' Asn-24' Asn-55' Asn-52 Asn-78

## velusetragum

## velusetrag

*N*-{[(1*R*,3*r*,5*S*)-8-[(2*R*)-2-hydroxy-3-(*N*-methanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-(propan-2-yl)-1,2-dihydroquinoline-3-carboxamide


## vélusétrag

*N*-{[(1*R*,3*r*,5*S*)-8-[(2*R*)-2-hydroxy-3-(*N*-méthylmethanesulfonamido)propyl]-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-1-(propan-2-yl)-1,2-dihydroquinoline-3-carboxamide

## velusetrag

*N*-{[(1*R*,3*r*,5*S*)-8-[(2*R*)-2-hidroxi-3-(*N*-metilmetanosulfonamido)propil]-8-azabicyclo[3.2.1]octan-3-il]-2-oxo-1-(propan-2-il)-1,2-dihidroquinolina-3-carboxamida

$C_{25}H_{36}N_4O_5S$



## zaurategrastum

## zaurategrast


(2*S*)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-{4-[(2,7-naphthyridin-1-yl)amino]phenyl}propanoic acid

## zauratégrast

acide (2*S*)-2-[(2-bromo-3-oxospiro[3.5]non-1-én-1-yl)amino]-3-{4-(2,7-naphthyridin-1-ylamino)phényl}propanoïque

## zaurategrast

ácido (2*S*)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-il)amino]-3-{4-[(2,7-naftiridin-1-il)amino]fenil}propanoico



- # Electronic structure available on Mednet: <http://mednet.who.int/>
- # Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- # Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.